Abionyx Pharma announces that it has carried out a capital increase of around three million euros (including premium) for the benefit of certain categories of individuals, designed to strengthen the biotech company's cash position.

This operation resulted in the full subscription of 2,967,352 new shares at a price of 1.011 euros per share, representing around 10.21% of the number of shares outstanding before issue and 9.27% after issue.352 new shares at a price of 1.011 euros per share, representing approximately 10.21% of the number of shares outstanding before the issue and 9.27% after the issue.

The aim of this fund-raising is to strengthen Abionyx's cash position in the context of its development in sepsis, and to ensure its financial visibility, which is now extended to the first quarter of 2025 without any further drawdown of the ORA.

Copyright (c) 2023 CercleFinance.com. All rights reserved.